SCHEMBL4996877

SCHEMBL4996877

CC(=O)c1ccc(N2CCN(c3cncc(-c4cccc(C)c4C)n3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 8/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHEK1 O14757 2/20 0.42
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
CNR2 P34972 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
GRIN2B Q13224 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
PIM2 Q9P1W9 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4987334 0.85 NPC1 (0.45) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL4992025 0.84 NPC1 (0.47) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL4996035 0.82 SMN1; SMN2 (0.49) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL5003195 0.80 PIM2 (0.50) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL4991693 0.80 LMNA (0.49) MAPTSMN1; SMN2CHEK1ALDH1A1KMT2A
SCHEMBL4993330 0.80 CHEK1 (0.57) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL5003303 0.79 MAPT (0.48) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL4995201 0.78 MAPT (0.44) NPC1RAB9AMAPTSMN1; SMN2CHEK1
SCHEMBL4995538 0.77 HTR7 (0.42) NPC1RAB9AMAPTSMN1; SMN2CNR2
SCHEMBL4997496 0.77 MAPT (0.51) NPC1RAB9AMAPTSMN1; SMN2CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C NPC1 2008/4885RAB9A 2969/4885MAPT 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.